A Phase 3 interventional study of Cariprazine and Placebo in Mania and Bipolar I Disorder, sponsored by Forest Laboratories. Completed at 66 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-04-12.
Sponsored by Forest Laboratories (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies in Mania with a site in United States — 5 open to participants now, 5 under way, 4 of them phase 3. Mania · United States.
Among the 94 studies in Mania with a site in United States, this one is the 5th largest by enrollment of the 88 interventional ones that give a count, is one of 9 that started in 2010, is one of 32 in phase 3, and was the 64th registered.
167 studies on the registry are indexed under Mania; 14 are open to participants now.
Browse Mania studies →5 of the 94 studies in Mania with a site in United States are open now. Recruiting first, the newest first:
Neurocrine Biosciences · Sites in United States
Ages 18–65
Bristol-Myers Squibb · Sites in United States, Argentina, Bulgaria and 10 more countries
Ages 18–65
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 17 more countries
Ages 18–65
Bristol-Myers Squibb · Sites in United States, China, Croatia and 8 more countries
Ages 18–65
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 6 more countries
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Mania studies recruiting now, 5 (42%) set no upper age limit and 7 (58%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 20 · Phase 3 33 · Phase 4 27
First in 1991; this study’s year is marked. 9 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 497 is above the median of 89 across 139 interventional studies indexed under Mania.
Median enrollment 83 across the 88 interventional studies, 155 across the 6 observational. Of the 87 that completed or were terminated, 40 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 94 have an industry lead sponsor. The 10 most frequent:
This study is registered under Forest Laboratories, one of the names counted as AbbVie. Under that name alone:
Forest Laboratories is the lead sponsor of 168 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
AbbVie has 6 studies filed under Mania — fewer than ten, so there is no comparison to draw.
1 of the studies in Mania with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07140913Phase 3Bristol-Myers SquibbA Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine | 2027-06-28 |
Add it to your calendar (.ics) → With an account.
Among the 94 studies in Mania with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine monotherapy versus placebo for the treatment of acute manic or mixed episodes associated with bipolar I disorder.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cariprazine 3 milligrams (mg) - 6 mg capsules oral administration, once per day for 3 weeks.
Drug: Cariprazine
Cariprazine 6 mg - 12 mg capsules oral administration, once per day for 3 weeks.
Drug: Cariprazine
Placebo dose-matching cariprazine capsules oral administration, once per day for 3 weeks.
Drug: Placebo
Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for three weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for three weeks.
Change From Baseline in the Young Mania Rating Scale (YMRS) Total Score at Week 3
The YMRS is an 11-item scale that assesses manic symptoms based on the participant's perception of his or her condition over the previous 48 hours, as well as the physician's clinical observations during the interview. The 11-items are elevated mood, increased motor activity-energy, sexual interest, sleep, irritability, rate and amount of speech, language-thought disorder, content, disruptive-aggressive behavior, appearance, and insight. The severity of the abnormality for 7-items are rated on a five-point scale (0-4) and 4-items on a nine-point scale (0-8). The individual scores are summed for a total possible score of 0 (best) to 60 (worst). A negative change from Baseline indicates improvement. Analysis is a mixed model for repeated measurements (MMRM) using observed cases, with treatment group, pooled study center, visit, treatment group-by-visit interaction as factors, baseline value and baseline-by-visit interaction as covariates and an unstructured covariance matrix.
Time frame: Baseline, Week 3
Change From Baseline in Clinical Global Impression-Severity (CGI-S) Total Score at Week 3
The CGI-S measures the investigator's assessment of overall severity of the participant's illness compared with the severity of illness in other patients the physician has observed using a 7-point scale (1=Normal, not ill at all to 7= Among the most extremely ill participants). A negative change from Baseline indicates improvement. Analysis is based on a MMRM using the observed cases data, with treatment group, pooled study center, visit, treatment group-by-visit interaction as factors, baseline value and baseline-by-visit interaction as covariates and an unstructured covariance matrix.
Time frame: Baseline, Week 3
| Milestone | Placebo | Cariprazine (3-6 mg/Day) | Cariprazine (6-12 mg/Day) |
|---|---|---|---|
| Started | 161 | 167 | 169 |
| Completed | 122 | 129 | 119 |
| Not completed | 39 | 38 | 50 |
| Withdrew: Adverse event | 8 | 15 | 25 |
| Withdrew: Insufficient therapeutic response | 15 | 2 | 5 |
| Withdrew: Protocol violation | 1 | 1 | 2 |
| Withdrew: Withdrawal of consent | 14 | 18 | 17 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 |
| Withdrew: Other unspecified | 1 | 1 | 0 |
| Milestone | Placebo | Cariprazine (3-6 mg/Day) | Cariprazine (6-12 mg/Day) |
|---|---|---|---|
| Started | 144 | 146 | 148 |
| Completed | 139 | 146 | 141 |
| Not completed | 5 | 0 | 7 |
The YMRS is an 11-item scale that assesses manic symptoms based on the participant's perception of his or her condition over the previous 48 hours, as well as the physician's clinical observations during the interview. The 11-items are elevated mood, increased motor activity-energy, sexual interest, sleep, irritability, rate and amount of speech, language-thought disorder, content, disruptive-aggressive behavior, appearance, and insight. The severity of the abnormality for 7-items are rated on a five-point scale (0-4) and 4-items on a nine-point scale (0-8). The individual scores are summed for a total possible score of 0 (best) to 60 (worst). A negative change from Baseline indicates improvement. Analysis is a mixed model for repeated measurements (MMRM) using observed cases, with treatment group, pooled study center, visit, treatment group-by-visit interaction as factors, baseline value and baseline-by-visit interaction as covariates and an unstructured covariance matrix.
| score on a scale | Placebo | Cariprazine (3-6 mg/Day) | Cariprazine (6-12 mg/Day) |
|---|---|---|---|
| Change From Baseline in the Young Mania Rating Scale (YMRS) Total Score at Week 3 | -12.5 ± 0.8 | -18.6 ± 0.8 | -18.5 ± 0.8 |
The CGI-S measures the investigator's assessment of overall severity of the participant's illness compared with the severity of illness in other patients the physician has observed using a 7-point scale (1=Normal, not ill at all to 7= Among the most extremely ill participants). A negative change from Baseline indicates improvement. Analysis is based on a MMRM using the observed cases data, with treatment group, pooled study center, visit, treatment group-by-visit interaction as factors, baseline value and baseline-by-visit interaction as covariates and an unstructured covariance matrix.
| score on a scale | Placebo | Cariprazine (3-6 mg/Day) | Cariprazine (6-12 mg/Day) |
|---|---|---|---|
| Change From Baseline in Clinical Global Impression-Severity (CGI-S) Total Score at Week 3 | -1.3 ± 0.1 | -1.9 ± 0.1 | -1.9 ± 0.1 |
Collected over First dose of study drug to 30 days past last dose (Up to 51 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 5/161 (3.1%) | 63/161 (39.1%) |
| Cariprazine (3-6 mg/Day) | — | 9/167 (5.4%) | 89/167 (53.3%) |
| Cariprazine (6-12 mg/Day) | — | 5/169 (3%) | 90/169 (53.3%) |
| Event | Placebo | Cariprazine (3-6 mg/Day) | Cariprazine (6-12 mg/Day) |
|---|---|---|---|
| ManiaPsychiatric disorders | 3/161 | 3/167 | 3/169 |
| Bipolar disorderPsychiatric disorders | 1/161 | 1/167 | 0/169 |
| Bipolar I disorderPsychiatric disorders | 1/161 | 1/167 | 1/169 |
| AggressionPsychiatric disorders | 0/161 | 1/167 | 0/169 |
| Endometrial cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/161 | 1/167 | 0/169 |
| HospitalisationSurgical and medical procedures | 0/161 | 1/167 | 0/169 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/161 | 1/167 | 0/169 |
| DepressionPsychiatric disorders | 0/161 | 0/167 | 1/169 |
| Event | Placebo | Cariprazine (3-6 mg/Day) | Cariprazine (6-12 mg/Day) |
|---|---|---|---|
| AkathisiaNervous system disorders | 8/161 | 29/167 | 38/169 |
| HeadacheNervous system disorders | 15/161 | 19/167 | 20/169 |
| NauseaGastrointestinal disorders | 9/161 | 16/167 | 19/169 |
| ConstipationGastrointestinal disorders | 5/161 | 8/167 | 18/169 |
| InsomniaPsychiatric disorders | 15/161 | 16/167 | 17/169 |
| Extrapyramidal disorderNervous system disorders | 8/161 | 16/167 | 12/169 |
| VomitingGastrointestinal disorders | 10/161 | 15/167 | 14/169 |
| RestlessnessPsychiatric disorders | 8/161 | 15/167 | 10/169 |
| DiarrhoeaGastrointestinal disorders | 12/161 | 4/167 | 9/169 |
| DyspepsiaGastrointestinal disorders | 5/161 | 7/167 | 10/169 |
Safety Population included all participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Placebo | Cariprazine (3-6 mg/Day) | Cariprazine (6-12 mg/Day) | Total |
|---|---|---|---|---|
| Mean | 41.5 ± 11.4 | 43.1 ± 12.2 | 41.2 ± 11.3 | 41.9 ± 11.7 |
| Sex: Female, Male(Participants) | Placebo | Cariprazine (3-6 mg/Day) | Cariprazine (6-12 mg/Day) | Total |
|---|---|---|---|---|
| Female | 72 | 77 | 84 | 233 |
| Male | 89 | 90 | 85 | 264 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Cariprazine (3-6 mg/Day) | Cariprazine (6-12 mg/Day) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 10 | 10 | 4 | 24 |
| Not Hispanic or Latino | 151 | 157 | 165 | 473 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | Cariprazine (3-6 mg/Day) | Cariprazine (6-12 mg/Day) | Total |
|---|---|---|---|---|
| White | 114 | 117 | 114 | 345 |
| Black/African American | 44 | 44 | 51 | 139 |
| Asian | 1 | 3 | 1 | 5 |
| American Indian or Alaska Native | 2 | 1 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 |
| Other | 0 | 1 | 1 | 2 |
| Weight(kilogram (kg)) | Placebo | Cariprazine (3-6 mg/Day) | Cariprazine (6-12 mg/Day) | Total |
|---|---|---|---|---|
| Mean | 81.70 ± 15.96 | 82.42 ± 16.22 | 81.49 ± 16.78 | 81.87 ± 16.30 |
| Height(centimeter (cm)) | Placebo | Cariprazine (3-6 mg/Day) | Cariprazine (6-12 mg/Day) | Total |
|---|---|---|---|---|
| Mean | 170.93 ± 9.88 | 170.99 ± 9.15 | 170.25 ± 9.36 | 170.72 ± 9.45 |
| Body Mass Index (BMI)(kg/meter(m)^2) | Placebo | Cariprazine (3-6 mg/Day) | Cariprazine (6-12 mg/Day) | Total |
|---|---|---|---|---|
| Mean | 27.99 ± 5.15 | 28.22 ± 5.29 | 28.04 ± 4.92 | 28.08 ± 5.12 |
The record gives a start of Feb 2010, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2017, 5 years 4 months after primary completion. A results delay was requested in Dec 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cariprazine